Table 1.
Clinical characteristics of the patients
| Characteristics | Value |
|---|---|
| Total number of patients | 51 |
| Age, year, mean ± SD (range) | 57.1 ± 11.3 (34–88) |
| No. of women (%) | 45 (88.2) |
| Tumor size, cm, mean ± SD (range) | 1.15 ± 0.81 (0.4–4.5) |
| SUVmax, median (range) | 5.67 (1.99–52.25) |
| MTV2.5, cm3, median (range) | 0.95 (0–29.35) |
| MTV3, cm3, median (range) | 0.72 (0–26.44) |
| MTV3.5, cm3, median (range) | 0.51 (0–24.86) |
| MTV4, cm3, median (range) | 0.39 (0–23.25) |
| TLG2.5, median (range) | 3.98 (0–407.08) |
| TLG3, median (range) | 3.34 (0–398.98) |
| TLG3.5, median (range) | 2.80 (0–393.78) |
| TLG4, median (range) | 1.99 (0–387.58) |
| Multifocality (%) | 16 (31.4) |
| Extrathyroidal extension (%) | 23 (45.1) |
| LN metastasis (%) | 26 (51.0) |
| Lateral LN metastasis (%) | 9 (17.6) |
| Advanced stage (%)a | 30 (62.0) |
Data are expressed as mean ± SD and median (range) for continuous variables and frequency (%) for categorical variables
SUV standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis
aAdvanced stage, TNM stage III and IV